IL1B and gastric cancer: Kai et al. [66] investigated IL-6 as a prognostic biomarker in patients with gastric cancer measuring IL-1β and IL-6, and found no significant difference in survival between patients with high tissue levels of IL-6 (cut-off level 50 pg/mg-protein) or IL-1β and low serum levels.